title: Eosinophil chemotactic activity in bronchoalveolar lavage fluid obtained from Toxocara canis-infected rats.
abstract: We examined eosinophil chemotactic activity (ECA) in bronchoalveolar lavage fluid (BALF) obtained from rats infected with Toxocara canis. For 4 weeks after infection, the number of eosinophils was determined in peripheral blood and BALF. ECA was assayed using a microchemotaxis chamber. Eosinophils in peripheral blood and BALF increased markedly after infection, peaking at 12 days and 2 weeks, respectively. ECA in BALF also increased significantly and peaked 2 weeks after infection. Partial characterization revealed that ECA was heat labile, lipid soluble, and resistant to trypsin digestion. Two ECA peaks were identified by molecular sieve column chromatography: one near the egg albumin marker (MW 45,000) and the other observed after elution with quinacrine (MW 472.9). Treatment with a specific leukotriene (LT) B4 receptor antagonist (ONO-4057), a platelet activating factor (PAF) receptor antagonist (TCV-309), and an anti-interleukin (IL)-5 monoclonal antibody (TB13) significantly reduced the ECA, suggesting that LTB4, PAF, and IL-5 contribute to the accumulation of eosinophils in the lungs of rats infected with T. canis.
authors.affiliation: First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Okada
authors.forename: K
authors.initials: K
authors.lastname: Fujimoto
authors.forename: K
authors.initials: K
authors.lastname: Kubo
authors.forename: M
authors.initials: M
authors.lastname: Sekiguchi
authors.forename: K
authors.initials: K
authors.lastname: Sugane
mesh_terms: D000818:Animals; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D002634:Chemotaxis, Leukocyte; D004802:Eosinophilia / Q000150:complications / Q000276:immunology; D004804:Eosinophils / Q000276:immunology*; D015848:Interleukin-5 / Q000037:antagonists & inhibitors; D007546:Isoquinolines / Q000494:pharmacology; D008168:Lung / Q000166:cytology / Q000276:immunology*; D008297:Male; D010666:Phenylpropionates / Q000494:pharmacology; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors; D011726:Pyridinium Compounds / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D018102:Receptors, Leukotriene B4 / Q000037:antagonists & inhibitors; D044005:Tetrahydroisoquinolines; D017166:Toxocara canis / Q000276:immunology*; D014120:Toxocariasis / Q000150:complications / Q000276:immunology*
chemical_list: D015848:Interleukin-5; D007546:Isoquinolines; D010666:Phenylpropionates; D010980:Platelet Membrane Glycoproteins; D011726:Pyridinium Compounds; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D018102:Receptors, Leukotriene B4; D044005:Tetrahydroisoquinolines; C039351:platelet activating factor receptor; C067523:ONO-LB 457; C067430:TCV 309